OBJECTIVE: Gliomas are the most common primary tumours of the central nervous system. Snake venom, such as candoxin (CDX) isolated from Bungarus candidus, inhibits glioma cell proliferation. This study explored the gene regulation profile of CDX-treated human glioma Hs683 cells. METHODS: Using microarray technology and bioinformatics analyses the underlying molecular mechanism of action of CDX was evaluated by constructing gene regulation and proteinprotein interaction co expression networks. RESULTS: CDX treatment induced a large number of related genes at the transcriptional level. The MYC gene (v-myc myelocytomatosis viral oncogene homologue [avian]) had a key role in the response of Hs683 cells to CDX treatment. Activation of MYC upregulated NDRG1 (N-myc downstream regulated 1), WNT10B (wingless-type mouse mammary tumour virus integration site family, member 10B), CASP9 (caspase 9, apoptosis-related cysteine peptidase) and CDKN2A (cyclin-dependent kinase inhibitor 2A), and downregulated ID3 (inhibitor of DNA binding 3, dominant negative helix-loop-helix protein) and SLC1A4
Introduction
Gliomas are the most common primary tumours of the central nervous system, with glioblastomas being the most malignant form. 1 Although sophisticated conventional anticancer regimens are used to treat patients with gliomas, including neurosurgical resection, irradiation and chemotherapy, the disease invariably leads to death within months or years. 2 Studies indicate that several proteins extracted from snake venom can exert inhibitory effects on glioma cells. For example, contortrostatin, a snake venom disintegrin, specifically binds certain integrins on the surface of glioma cells and inhibits their interaction with the YX Jiang, Y Ma, Y Cheng Candoxin-induced differential gene expression extracellular matrix (ECM), blocking cell motility and invasiveness. 3, 4 Contortrostatin also improves overall survival in gliomabearing animals. 5 The peptides KD, KDII-3 and KDIII-1, purified from Naja naja atra (cobra) venom, significantly inhibit the proliferation of U251 glioma cells in a dosedependent manner, 6 and Dendroaspis angusticeps (Eastern green mamba) natriuretic peptide (100 µM) causes a 17% decrease in the number of human glioblastoma cells. 7 Apoxin protein-1 from Okinawa habu (Trimeresurus flavoviridis) venom significantly inhibits the growth of malignant glioma cell lines (rat C6 and human RBR 17T and U251), and this effect may be mediated via promotion of the generation of intracellular reactive oxygen species and tumour suppressor p53 protein in glioma cells. 8 Candoxin (CDX) is a three-finger neurotoxin purified from the venom of the Malayan krait (Bungarus candidus), and consists of a single polypeptide chain of 66 amino acid residues with five disulphide bridges. 9 CDX produces reversible, postsynaptic neuromuscular blockade of αβγδ nicotinic acetylcholine receptors (nAChRs) in avian and mammalian neuromuscular junctions, but irreversibly antagonizes neuronal α7 nAChRs, thereby affecting synaptic neurotransmission and producing flaccid paralysis. 9, 10 Research has demonstrated that a 16-residue peptide, derived from the loop II region of CDX, could enable drug delivery to the brain and inhibit tumour growth in intracranial glioblastomabearing mice. 11 CDX has also been shown to cause death in the human glioma cell line Hs683 in a dose-and time-dependent manner by inducing a series of inflammation-and apoptosis-related genes. 12 These findings suggest that CDX may be a potential candidate for clinical glioma chemotherapy. In order to identify fully the biological actions of CDX in glioma cells, a better understanding of gene regulation and coexpression profiles and the molecular pathways involved is essential.
To provide the theoretical basis for further research into the use of CDX as an anticancer therapy, the present study used microarray technology and bioinformatics analyses to explore the gene regulation profiles between transcription factors and differentially expressed genes (DEGs), and between different DEGs, in CDX-treated human glioma Hs683 cells, with a view to obtaining information on the pathways activated by CDX.
Materials and methods

PATHWAY DATA SOURCE
Pathway data were collected from the Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY database (available at http://www.genome.jp/kegg/). 13 A total of 130 pathways involving 2287 genes were obtained. YX Jiang, Y Ma, Y Cheng Candoxin-induced differential gene expression com/pub/databases.html) and the Transcriptional Regulatory Element Database 17 (TRED; available at http://rulai. cshl.edu/TRED/). A total of 6328 regulation relationships between 276 transcription factors and 3002 target genes were collected.
MICROARRAY DATA
The transcription profile dataset GSE1682 (based on global gene expression analysis of human glioma Hs683 cells exposed to CDX, obtained using the Affymetrix Human Genome U133A 2.0 Array [Affymetrix, Santa Clara, CA, USA] 12 ) was obtained from the NCBI GEO database (available at http://www. ncbi.nlm.nih.gov/geo/). The Hs683 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in 72-cm 2 flasks at a density of 1 × 10 7 cells/12 ml in Dulbecco Modified Eagle Medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin, at 37°C with 5% carbon dioxide in a humidified atmosphere. The lyophilized form of B. candidus venom was obtained from Venom Supplies Pty Ltd (Tanunda, Australia) and CDX was purified as described previously, 9 with minor modifications.
The Hs683 cells were grown to 40% confluency for 24 h before treatment with CDX at a predetermined dose (EC 50 1 µM) 12 for 12, 24 or 48 h (n = 3 flasks at each timepoint). Untreated Hs683 cells (n = 3 flasks) were included as a control. Total RNA was extracted using the RNeasy ® Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Preparation and processing of labelled, fragmented cRNA for oligonucleotide microarray hybridization were performed according to Affymetrix protocols. The quality of labelled target cRNA was initially assessed using GeneChip ® Test3 arrays (Affymetrix). Human Genome U133A
GeneChip expression arrays (Affymetrix) were hybridized for 16 h at 45°C on a shaking platform at 60 rpm. 12
ANALYSIS OF DEGS
The Limma method was used to identify DEGs in the GSE1682 dataset. 18 The original expression datasets from all conditions were extracted into expression estimates and used to construct the linear model. Only DEGs with a fold-change > 2 and a P-value < 0.05 were selected.
COEXPRESSION NETWORK CONSTRUCTION
To determine potential PPIs, Pearson's correlation coefficient (PCC) was calculated for all pair-wise comparisons of gene expression values between transcription factors and DEGs. PPI relationships with PCCs > 0.75 were considered significant. Interactions between two DEGs were matched using PPI data from HPRD and BioGRID. The interaction was selected as a candidate relationship if PCC was > 0.75.
REGULATION NETWORK CONSTRUCTION
Relationships between transcription factors and their target DEGs were matched using regulation data collected from TRANSFAC ® and TRED. The regulation network was constructed using Cytoscape software, version 2.8.0 (available at http://www. cytoscape.org/), with PCC > 0.75 for transcription factors and their target DEGs. 19
GENE ONTOLOGY
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 20 was used to identify over-represented gene ontology (GO) categories in biological processes based on the hypergeometric distribution, with count > 2 and false discovery rate < 0.05.
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Results
Analysis of GSE1682 using the limma method identified a total of 1222 DEGs with a fold-change > 2 and P-value < 0.05.
In total, 44 regulation relationships were selected, including 20 transcription factors and their 26 target DEGs, and a regulation network was built between transcription factors and their target DEGs in CDX-treated glioma cells (Fig. 1 ). The proto-oncogene protein c-Myc (MYC a ) was identified as both a transcription factor and a DEG and was categorized at a higher level than other genes in the local network. MYC induced transcription of NDRG1, WNT10B, CASP9 and CDKN2A and inhibited transcription of ID3 and SLC1A4. The transcription factors FOS and PLAU suppressed each other. There was a reverse regulation relationship between the transcription factors POU2F1 and SP1, such that SPP1 was suppressed by POU2F1 and activated by SP1.
A coexpression network with a total of 355 nodes and 296 interactions was constructed based on PPI datasets. The nodes for SPP1, CD44, FN1 and SDC1 formed a subnetwork, 
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as did the nodes for MYC, CDKN2A, PRKCZ, CASP9 and PIN1 (Fig. 2) .
The functions of the regulation and coexpression networks were described using GO terms. Several GO categories were enriched in each network. The top 10 enriched GO terms for each network are shown in Table 1 .
Discussion
The present study explored the underlying molecular mechanisms of the response of glioma cells to CDX treatment by constructing regulation and coexpression networks, and showed that there was consistency between these two networks. MYC was found to have an important role in the response of glioma cells to CDX treatment via transcriptional induction of a number of genes, including NDRG1, WNT10B, CASP9 and CDKN2A, and transcriptional inhibition of ID3 and SLC1A4. These genes were predicted to be involved in glioma cell proliferation, invasiveness and apoptosis.
The Myc family of proteins is thought to play a crucial role in cellular proliferation, differentiation, transformation and FIGURE 2: Coexpression network between transcription factors (triangles) and target genes (circles) for candoxin-treated human glioma Hs683 cells. The network was constructed using protein-protein interaction (PPI) datasets from the Human Protein Reference Database 14 and the BioGRID Interaction Database. 15 Light grey nodes indicate differentially expressed genes, dark grey nodes indicate normally expressed genes and connecting lines indicate PPIs. Gene names are defined in full in the Glossary at the end of this article YX Jiang, Y Ma, Y Cheng Candoxin-induced differential gene expression apoptosis. 21 Injection of the s-MYC gene together with C6 glioma cells completely prevented the formation of both brain and subcutaneous tumours derived from the parental glioma cells. 22 Furthermore, the transactivation activity of s-Myc protein through sequence-specific DNA binding may be required for the induction of programmed cell death in glioma cells. 23 Proteasome inhibitors caused the accumulation of c-Myc protein in human glioma cells, transiently inducing the upregulation of Fas ligand mRNA and stimulating the Fas receptor-ligand apoptotic signalling pathway. 24 The present study suggested that treatment of glioma cells with CDX induced upregulation and accumulation of c-Myc protein, which could, in turn, promote glioma cell apoptosis.
The cellular protein NDRG1 (also known as Cap43, Drg-1 and rit42) is present in various normal tissues and is upregulated in many stress and growth-regulatory conditions. 25 NDRG1 deficiency results in neural defects in mice. 26 20 The 10 highest-rated categories are shown for each network patients with NDRG1-negative gliomas is lower than that of NDRG1-positive patients. 27 The loss of NDRG1 protein has been shown to be a significant and independent prognostic indicator in glioma. 27 Upregulation of NDRG1 has been found to inhibit glioma cell migration. 28 Activation of MYC led to increased NDRG1 expression in response to CDX treatment in the present study. Evidence suggests that aberrant activation of the WNT protein signalling pathway is involved in glioma development and progression. 29 WNT10B mRNA is highly downregulated in NT2 cells treated with retinoic acid. 30 This may result in incorrect functioning of the WNT/β-catenin signalling pathway and aberrant cell proliferation, partly explaining the progression of glioblastoma. 31 Expression of WNT10B was upregulated in response to increased MYC activity following treatment with CDX in the present study, suggesting that upregulation of WNT10B might inhibit glioma cell proliferation.
Research has demonstrated that transduction of caspase-9 might override the resistance mechanism of the human glioma cell line U87MG to p53-mediated apoptosis. 32, 33 N-myc has also been implicated in apoptosis induction, in particular the activation of caspase-9mediated apoptosis. Ectopic N-myc induced susceptibility to tumour necrosis factor-related apoptosis-inducing ligand, via both caspase-8-and caspase-9-mediated apoptosis. 34 In the present study, CASP9 expression was upregulated in response to increased c-Myc activity following CDX treatment, which might, in turn, induce glioma cell apoptosis.
Cyclin-dependent kinase inhibitor 2A (CDKN2A) has been shown to block murine double minute (Mdm2)-induced degradation of p53, which enhances p53-dependent transactivation and apoptosis. 35 CDKN2A also binds to cyclin-dependent kinase 4 (CDK4) and CDK6 and suppresses proliferation by inhibiting progression from G 1 to S phase. 36 The CDKN2A gene is expressed at lower levels in patients with high-grade malignant glioma than in those with low-grade glioma. 37 CDKN2A overexpression inhibits the growth of glioma cell lines by suppressing cyclin D 1 . 37 All tumours, including gliomas, contain a population of cancer-initiating stem cells that are thought to be responsible for tumorigenesis, relapse and therapeutic resistance. In gliomas these are known as glioma-initiating cells (GICs). 38, 39 Inhibitors of transforming growth factor (TGF)-β targeted to the GIC compartment in human glioblastoma patients resulted in reduced expression of the transcription factor genes ID3 and ID1. 40 Inhibition of the TGF-β pathway decreased the CD44 high /Id1 high GIC population via repression of ID1 and ID3, thereby inhibiting the capacity of cells to initiate glioblastoma development. 40 In addition, signalling through the epidermal growth factor receptor (EGFR) regulates proliferation, angiogenesis and acquisition of glioma stem-like cell (GSC) characteristics by inducing ID3 expression and ID3regulated cytokines (chemokine [C-X-C motif] ligand 1 [previously known as GRO1], interleukin-6 [IL-6] and IL-8). 41 Conversely, inhibitors of EGFR suppress the EGFR-AKT-Smad5-driven induction of ID3, leading to a decrease in the tumorsphere-forming ability of GSC and U87MG cells. 41 Downregulation of ID3 might inhibit glioma cell initiation and proliferation. MYC and ID3 have been found to be coexpressed in the human glioma cell line T98G. 42 ID3 expression was inhibited by MYC in response to CDX treatment in the present study, suggesting that downregulation of ID3 could inhibit glioma cell proliferation.
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The SLC1A4 gene (also known as ASCT1) contributes predominantly to the uptake of L-serine in C6 glioma cells. 43, 44 Inhibition of SLC1A4 by MYC may reduce glioma cell proliferation due to reduced uptake of this nonessential amino acid.
The present study demonstrated that SPP1 plays an important role in glioma cells. SPP1 expression was inhibited by POU2F1 and promoted by SP1 in response to CDX treatment. SPP1 encodes osteopontin, a phosphorylated glycoprotein containing a functional
Gly-Arg-Gly-Asp-Ser cellbinding sequence. 45 Osteopontin mRNA levels are increased in human malignant glioma, 46 and osteopontin is one of the largest ECM components in U87MG cells that are able to counteract G5-dependent necrotic death. 47 The inhibitory effect of POU2F1 in response to CDX treatment may, therefore, exceed the SPP1 gene expression promoting effects of SP1, ultimately leading to malignant glioma cell apoptosis.
Syndecan-1 (SDC1) is an ECM component in glioma cell lines and participates in glioma cell migration via interactions with thrombospondin-1. 48 The transmembrane adhesion molecule CD44 is found on the surface of all gliomas and is involved in human glioma cell invasion, probably through its role in cell interactions with ECM proteins. 49 CD44 antagonists can inhibit glioma growth in preclinical mouse models. 50 CDX treatment may have inhibited cell proliferation via interactions with ECM components in the present study.
Protein kinase C (PKC)-ζ is a member of the PKC family of serine/threonine kinases that have been implicated in a variety of cellular processes, including proliferation, differentiation and secretion. 51 The rapid growth of gliomas has been attributed to inherently high levels of PKC. 52 Treatment of human glioma U373 cells with the PKC inhibitor calphostin C inhibited PKC activity, increased the number of cells in S phase and exhibited potent cytotoxic effects. 53 Higher concentrations of calphostin C induced an additional block in G 2 /M phase in U373 cells. 53 Treatment of the highly PKC-activating glioblastoma cell line U87MG with a branched glycoglycerolipid analogue inhibited PKC translocation and activation which, in turn, reduced cell proliferation and migration. 54 PRKCZ expression was decreased by CDX treatment in the present study, and this may contribute to inhibition of cell proliferation.
In conclusion, the present study demonstrated that treatment with CDX inhibits glioma cell proliferation and promotes apoptosis via transcriptional induction or inhibition of a large number of related genes. Regulation and coexpression networks indicated that MYC exerts a crucial role in regulating the transcriptional response of glioma cells to CDX via increased expression of NDRG1, WNT10B, CASP9 and CDKN2A, and decreased expression of ID3 and SLC1A4. In addition, a subnetwork of protein-protein interactions exists among SPP1, SDC1 and CD44, and these genes are predicted to be involved in glioma cell invasion. A clearer understanding of the interactions between transcription factors and DEGs in glioma cells might provide novel therapeutic targets for glioma chemotherapy.
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